Sponsor of the Day:
Jerkmate
https://www.genengnews.com/companies/sarepta-therapeutics/
Sarepta Therapeutics Archives - GEN - Genetic Engineering and Biotechnology News
therapeutics archives gengenetic engineeringbiotechnology newssarepta
https://www.biospace.com/policy/regenxbio-secures-legal-win-in-gene-therapy-patent-battle-vs-sarepta
REGENXBIO Secures Legal Win in Gene Therapy Patent Battle Vs. Sarepta - BioSpace
Feb 23, 2026 - A lower court had previously ruled for Sarepta in the companies’ long-running dispute, finding that REGENXBIO’s AAV patent was invalid because its elements...
secures legalgene therapypatent battleregenxbiowin
https://www.leduc-county.com/county-government/notices/post/public-notice-naming-of-unnamed-street-in-new-sarepta-to-dennis-levasseur-street
Public notice: Naming of unnamed street in New Sarepta to Dennis Levasseur Street: Notices - Leduc...
Learn about what's happening today in Leduc County, including upcoming events, road closures and County updates.
public noticenamingunnamedstreetnew
https://www.biospace.com/drug-development/sarepta-plans-fda-run-for-duchenne-exon-skippers-despite-confirmatory-trial-failure
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure - BioSpace
Mar 19, 2026 - Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether...
trial failuresareptaplansfdarun
https://www.biospace.com/business/caught-in-sarepta-downdraft-arrowhead-becomes-rnai-knight-in-shining-armor
Caught In Sarepta ‘Downdraft,’ Arrowhead Becomes RNAi Knight in Shining Armor - BioSpace
Aug 12, 2025 - Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline this past month. BioSpace caught up...
shining armorcaughtsareptaarrowheadbecomes
https://www.biospace.com/business/after-mortality-marred-year-sarepta-looks-ahead-to-catalyst-rich-2026
After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026 - BioSpace
Jan 13, 2026 - Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral muscular dystrophy and myotonic...
looks ahead2026 biospacemortalitymarredyear
https://www.fool.com/investing/2024/10/03/better-biotech-stock-wave-life-sciences-vs-sarepta/
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics | The Motley Fool
Oct 3, 2024 - These two could become direct competitors relatively soon.
wave lifemotley foolbetterbiotechstock
https://www.biopharmadive.com/news/sarepta-doug-ingram-ceo-retire-duchenne/813169/
Sarepta CEO Doug Ingram to retire, with company at a crossroads | BioPharma Dive
Ingram, who steered the company through multiple drug approvals and controversies, will step aside as Sarepta faces dwindling Elevidys sales and emerging...
biopharma divesareptaceodougingram
https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-embark-data/810461/
Sarepta, battling slowing sales, claims Duchenne gene therapy’s impact grows with time | BioPharma...
On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” surrounding Elevidys.
slowing salessareptabattlingclaimsduchenne